Immunotherapy Drugs Market - Growth, Trends, and Forecasts (2020 - 2025)

The Immunotherapy Drugs Market is segmented by Type of Drug, Therapy Area, and Geography.

Immunotherapy Drugs Market Snapshot

Study Period:

2017-2025

Base Year:

2019

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

CAGR:

13 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The immunotherapy drugs market is anticipated to record a CAGR of 13% during the forecast period. The major factors attributing to the growth of the immunotherapy drugs market are the rising adoption of targeted therapy over traditional therapy, emergence of biosimilars, rising prevalence of chronic diseases and lifestyle disorders, and rising demand for monoclonal antibodies. Furthermore, immunotherapy is widely used in cancer treatment

For instance, over the past decade, there has been a continuous rise in the prevalence of several chronic diseases, which, in several cases, need immune-based therapies. Some of the major chronic diseases include cancer, kidney failure, and heart diseases. Several lifestyle disorders, both chronic and non-communicable diseases, such as hypertension, diabetes, obesity, and depression, need critical care during hospitalization. Thus, the rise in the number of diseases and associated disorders is among the major primary reasons for the growth of this immunotherapy drugs market.

Scope of the Report

Immunotherapy relates to a type of biologic therapy for cancer treatment to boost the body’s natural defences to fight cancer. It may work in stopping or slowing the growth of cancer cells, stopping cancer from spreading in other parts of the body, and in the improvement of the immune system. These therapies are made by the body or in a laboratory, to improve or restore the immune system function.

By Type of Drug
Monoclonal Antibodies
Vaccines
Interferons Alpha and Beta
Interleukins
Other Types of Drugs
By Therapy Area
Cancer
Autoimmune and Inflammatory Diseases
Infectious Diseases
Other Therapy Areas
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East & Africa
GCC
South Africa
Rest of Middle-East & Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Cancer is Expected to Hold the Major Share in the Therapy Area Segment

  • Cancer is an abnormal growth of the cells in the body. There are more than 100 different types of cancer. According to the World Cancer Research Fund, in 2018, there were an estimated 18 million cancer cases around the world, out of which, 9.5 million cases were in men and 8.5 million in women. This cancer prevalence is expected to be the same in the coming years, which is helping the market to grow.
  • There are several types of immunotherapies used for the treatment of cancer. Some of the immunotherapies include immune checkpoint inhibitors, T-cells cell transfer, cancer vaccines, and immune system modulators.​
  • These therapies are used for many types of cancer and their advanced stages. The side-effects of cancer immunotherapy vary, depending upon the immunotherapy being used. Some of the popular immunotherapy drugs are Rituxan, Yervoy, Adcetris, and Zevalin, among several others.​
  • The growth of immunotherapies in developed markets is high, due to increased R&D, with better government policies for supporting clinical trials through findings and campaigns, in order to raise awareness regarding several kinds of cancer.

To understand key trends, Download Sample Report

North America Dominates the Market and is Expected to do Same in the Forecast Period

North America is expected to have a significant market share throughout the forecast period. This is due to the increasing incidence of cancers, rising geriatric population, growing preference, and adoption rate of immunotherapy rates across the region. 

According to the estimates of the American Cancer Society,  in 2018, there would be 1,735,350 new cancer cases diagnosed and 609,640 deaths, due to cancer in the United States. The most common cancers in the United States are breast cancer, lung cancer, prostate cancer, colorectum cancer, bladder cancer, and skin cancer.​ 

In the North American region, the United States holds the largest market share. Factors, such as increased awareness among people for the early detection of diseases, better reimbursement policies, healthcare expenditure with better infrastructure, and rising prevalence of chronic and lifestyle disorders are the primary factors propelling the immunotherapy market in the United States. In March 2019, Roche’s Tecentriq in combination with Abraxane received U.S.FDA accelerated approval for people with PD-L1-positive, metastatic triple-negative breast cancer. Tecentriq combination is the first cancer immunotherapy regimen approved for breast cancer.

To understand geography trends, Download Sample Report.

Competitive Landscape

The immunotherapy drugs market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. The market players are focusing on new product launches R&D, expansions to gain competitive advantage. In August 2019, U.S.FDA approved pexidartinib (TURALIO, Daiichi Sankyo) capsules for adult patients with symptomatic tenosynovial giant cell tumor (TGCT). Some of the major players of the market are AbbVie Inc., Amgen Inc., AstraZeneca, GlaxoSmithKline PLC, and F. Hoffmann-La Roche AG, among others.

You can also purchase parts of this report. Do you want to check out a section wise price list?

Table Of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Adoption of Targeted Therapy over Traditional Therapy

      2. 4.2.2 Emergence of Biosimilars

      3. 4.2.3 Rising Prevalence of Chronic Diseases and Lifestyle Disorders

      4. 4.2.4 Rising Demand for Monoclonal Antibodies

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Immunotherapy Treatment

      2. 4.3.2 High Attrition Rate in the Product Development Cycle

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Type of Drug

      1. 5.1.1 Monoclonal Antibodies

      2. 5.1.2 Vaccines

      3. 5.1.3 Interferons Alpha and Beta

      4. 5.1.4 Interleukins

      5. 5.1.5 Other Types of Drugs

    2. 5.2 By Therapy Area

      1. 5.2.1 Cancer

      2. 5.2.2 Autoimmune and Inflammatory Diseases

      3. 5.2.3 Infectious Diseases

      4. 5.2.4 Other Therapy Areas

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East & Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East & Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AbbVie Inc.

      2. 6.1.2 Amgen Inc.

      3. 6.1.3 AstraZeneca plc

      4. 6.1.4 Bristol-Myers Squibb

      5. 6.1.5 F. Hoffmann-La Roche AG

      6. 6.1.6 GlaxoSmithKline plc

      7. 6.1.7 Johnson & Johnson

      8. 6.1.8 Merck & Co. Inc.

      9. 6.1.9 Novartis AG

      10. 6.1.10 UbiVac

  7. *List Not Exhaustive
  8. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape Covers- Business Overview, Financials, Products and Strategies, and Recent Developments

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Related Reports